Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7a pseudogene 57 (RPL7AP57) is a processed pseudogene in the human genome that resembles the protein-coding gene for ribosomal protein L7a (RPL7A), a component of the 60S ribosomal subunit involved in protein synthesis. Unlike its parent gene, RPL7AP57 does not encode a functional protein and is not known to produce an active RNA transcript or to play a biological or pathological role. Pseudogenes like RPL7AP57 arise from gene duplication or retrotransposition events and accumulate mutations that prevent them from producing functional products. RPL7AP57 is not considered a therapeutic target, receptor, enzyme, or druggable protein, and it does not have any known molecular or clinical significance as a target in disease or therapy. The true functional gene is RPL7A, which encodes a structural ribosomal protein; RPL7AP57 is a pseudogene copy of RPL7A. No evidence suggests any biological function, disease association, or pharmacological targeting of RPL7AP57. This entry is not a molecular target or canonical drug target; thus, “is_target” is set to false and “is_incorrect” is set to true due to its non-functional, pseudogene status.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7a pseudogene 57 (RPL7AP57).